Home The crystal structure of 1-(1-adamantan-1-yl)ethyl-3-(3-methoxyphenyl)thiourea, C20H28N2OS
Article Open Access

The crystal structure of 1-(1-adamantan-1-yl)ethyl-3-(3-methoxyphenyl)thiourea, C20H28N2OS

  • Shahnez Chaouch , Mohamed El-Naggar , Ihsan A. Shehadi , Monther A. Khanfar ORCID logo and Raed A. Al-Qawasmeh EMAIL logo
Published/Copyright: April 15, 2024
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 239 Issue 3

Abstract

C20H28N2OS, triclinic, P1̄ (no. 2), a = 6.7356(10) Å, b = 10.8739(15) Å, c = 13.245(2) Å, α = 75.580(7)°, β = 78.612(7)°, γ = 87.564(7)°, V = 921.0(2) Å3, Z = 2, R gt(F) = 0.0796, wR ref(F 2) = 0.2666, T = 100(2) K.

CCDC no.: 2343337

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colourless needle
Size: 0.51 × 0.08 × 0.05 mm
Wavelength: MoKα radiation (0.71073 Å)
μ: 0.19 mm−1
Diffractometer, scan mode: Bruker Apex-II, φ and ω
θ max, completeness: 25.7°, >99 %
N(hkl)measured, N(hkl)unique, R int: 24,903, 3501, 0.088
Criterion for I obs, N(hkl)gt: I obs > 2σ(I obs), 2568
N(param)refined: 225
Programs: Bruker [1], Olex2 [2], Shelx [3, 4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z U iso*/U eq
C1 0.6504 (6) 0.7110 (3) 0.1087 (3) 0.0295 (8)
C2 0.4749 (6) 0.7794 (3) 0.1273 (3) 0.0300 (8)
H2A 0.3475 0.7427 0.1308 0.036*
C3 0.4841 (6) 0.9018 (3) 0.1409 (3) 0.0313 (8)
C4 0.6702 (6) 0.9549 (4) 0.1376 (3) 0.0375 (9)
H4 0.6780 1.0384 0.1466 0.045*
C5 0.8436 (6) 0.8840 (4) 0.1209 (4) 0.0416 (10)
H5 0.9705 0.9190 0.1209 0.050*
C6 0.8373 (6) 0.7637 (4) 0.1044 (3) 0.0372 (9)
H6 0.9586 0.7179 0.0904 0.045*
C7 0.3023 (7) 1.0913 (4) 0.1615 (3) 0.0404 (9)
H7A 0.1639 1.1241 0.1664 0.061*
H7B 0.3888 1.1413 0.0972 0.061*
H7C 0.3545 1.0977 0.2241 0.061*
C8 0.7251 (5) 0.4808 (3) 0.1234 (3) 0.0277 (8)
C9 0.9518 (6) 0.3741 (3) 0.2479 (3) 0.0308 (8)
H9 0.9503 0.3052 0.2103 0.037*
C10 0.8594 (5) 0.3181 (3) 0.3673 (3) 0.0278 (8)
C11 0.6540 (6) 0.2550 (4) 0.3782 (3) 0.0349 (9)
H11A 0.5608 0.3187 0.3457 0.042*
H11B 0.6725 0.1870 0.3395 0.042*
C12 0.5605 (6) 0.1984 (4) 0.4948 (3) 0.0370 (9)
H12 0.4267 0.1586 0.4996 0.044*
C13 0.7016 (6) 0.0976 (4) 0.5441 (3) 0.0388 (9)
H13A 0.7193 0.0286 0.5065 0.047*
H13B 0.6417 0.0605 0.6196 0.047*
C14 0.9068 (6) 0.1580 (4) 0.5356 (3) 0.0357 (9)
H14 0.9996 0.0918 0.5672 0.043*
C15 0.8783 (6) 0.2623 (4) 0.5960 (3) 0.0366 (9)
H15A 1.0109 0.3014 0.5915 0.044*
H15B 0.8202 0.2256 0.6719 0.044*
C16 0.7355 (6) 0.3634 (3) 0.5472 (3) 0.0351 (9)
H16 0.7163 0.4318 0.5866 0.042*
C17 0.8269 (6) 0.4210 (3) 0.4302 (3) 0.0317 (8)
H17A 0.9582 0.4622 0.4249 0.038*
H17B 0.7351 0.4869 0.3992 0.038*
C18 1.0001 (6) 0.2162 (4) 0.4180 (3) 0.0335 (8)
H18A 1.1333 0.2548 0.4130 0.040*
H18B 1.0217 0.1486 0.3790 0.040*
C19 0.5301 (6) 0.3027 (4) 0.5552 (3) 0.0364 (9)
H19A 0.4691 0.2660 0.6307 0.044*
H19B 0.4371 0.3679 0.5245 0.044*
C20 1.1679 (6) 0.4231 (4) 0.2244 (3) 0.0416 (10)
H20A 1.2577 0.3529 0.2475 0.062*
H20B 1.1754 0.4887 0.2626 0.062*
H20C 1.2099 0.4594 0.1479 0.062*
N1 0.6358 (5) 0.5907 (3) 0.0843 (2) 0.0308 (7)
H1 0.543 (7) 0.591 (4) 0.048 (4) 0.046*
N2 0.8261 (5) 0.4770 (3) 0.2016 (2) 0.0310 (7)
H2 0.829 (7) 0.550 (5) 0.218 (4) 0.046*
O1 0.3020 (4) 0.9610 (2) 0.1570 (2) 0.0385 (7)
S1 0.70211 (15) 0.35278 (9) 0.07474 (7) 0.0347 (4)

1 Source of materials

All chemicals and solvents were used as purchased without further purifications. The uncorrected melting point was determined using an electrothermal digital melting-point apparatus. The NMR spectra were recorded at room temperature in DMSO-d6 solution on a Bruker Avance 500 MHz NMR spectrometer. The title compound was prepared as follows: while stirring a solution of 1-(adamantan-1-yl)ethanamine hydrochloride (0.1 g, 0.55 mmol, 1.0 eq) in dichloromethane (DCM) (1.5 mL), Et3N (0.23 mL, 1.65 mmol, 3.0 eq) was added and followed with phenyl isothiocyanate (0.070 mL, 0.58 mmol, 1.05 eq) in DCM (1.0 mL) at 0 °C. After 14 h at room temperature, the reaction solution was diluted with H2O (3 mL) and DCM (5 mL). The organic layer was separated and concentrated to give crude residue which was then triturated with DCM/Pentane mixture (1:10, 20 mL) to afford the title compound, 1-(1-(adamantan-1-yl)ethyl)-3-(3-methoxyphenyl)thiourea as white color solid with 83 % yield (143 mg, 0.45 mmol). The obtained compound was recrystallized from methanol. Melting point: 152–154 °C. 1 H-NMR (500 MHz, DMSO-d6): δ 1.00 (d, 3H, J = 7.0 Hz), 1.50–1.53 (6H, m, adamantane-H), 1.60–1.69 (6H, m, adamantane-H), 1.97 (3H, bs, adamantane-H), 3.73 (3H, s, OCH3), 4.19 (1H, bt, J = 7.0 Hz), 6.64 (1H, dd, J = 2.0, 8.0 Hz), 7.01 (1H, dd, J = 1.0, 8.0 Hz), 7.19 (1H, bdd, J = 8.0, 8.5 Hz), 7.34 (1H, bs, NH), 7.42 (1H, bd, J = 9.5 Hz), 9.442 (1H, s, NH). 13 C-NMR (125 MHz, DMSO-d6); δ 13.8, 27.82, 36.66, 38.23, 55.09, 57.31, 107.87, 109.17, 114.36, 129.26, 140.98, 153.1, 180.02.

2 Experimental details

Single crystal of C20H28N2OS was obtained through crystallization of the pure compound from slow evaporation of methanol. The collected frames were integrated with the Bruker SAINT software package using a narrow-frame algorithm. Data correction was performed for absorption effects using the multi-scan method (SADABS). The structure was solved and refined using the Bruker Shelx [3] software package. Using Olex2 [2], the structure was further refined with the ShelXL [4] refinement package. All H atoms bonded to C atoms were refined as riding, with C–H distances of 0.93 Å (for aromatic ring).

3 Comment

The discovery of the adamantine and rimantadine (the superior one) as the first adamantane-based antiviral drugs [5, 6], has sparked the research and development of diverse entities that contain adamantane moiety. The adamantane nucleus has been proven to be lipophilic bullet in many approved drugs [7]. Adamantane containing compounds are still rising in the medicinal chemistry area with wide biological indications [8], [9], [10], [11], [12]. Thiourea derivatives, on the other hand, are well known for their biological activities in different areas of medicinal chemistry. The thiourea derivative sorafenib and regorafenib are marketed as anticancer drugs [13], anti-ad activity [14], and antibiotic [15]. As an ongoing program to investigate new hybrid systems with potential bioactivity [16, 17] we are focusing on the hybridization of rimantadine with the thiourea moiety via the reaction of the commercially available rimantadine hydrochloride to generate the new hybrid system.

The crystallographic measurement shows that the crystal structure consists of the C20H28N2OS monomeric molecules. The asymmetric unit shows one molecular unit, in which all bond lengths and angles are in normal ranges [18]. The molecules maintain the trans-cis configuration [19] with respect to the position of the phenyl group relative to the thiono S1 atom across N1–C1 and N2–C9 bonds, respectively. The thiourea moiety (S1/N1/N2/C8) is essentially planar with a maximum deviation of 0.007(3) Å for atom C8 from the least square plane. It makes dihedral angle with phenyl ring of 51.762(15)°.

The molecular packing of the title compound is affected by N1–H1⋯S1 intermolecular hydrogen bond, with distance equal to 2.495 Å, to form centrosymmetric dimers along c axis. An additional C5–H5⋯O1 (−1 + x, +y, +z) intermolecular hydrogen bond is observed with distance equal to 2.457 Å.

Corresponding author: Raed A. Al-Qawasmeh, Department of Chemistry, Pure and Applied Chemistry Group, College of Sciences, University of Sharjah, Sharjah, 27272, UAE; and Department of Chemistry, The University of Jordan, Amman, 11942, Jordan, E-mail:

Funding source: University of Sharjah

Award Identifier / Grant number: 23021440137

  1. Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This research work was funded by University of Sharjah, for financial support (grant No. 23021440137). Part of this work has been carried out during sabbatical leave granted to MAK from the University of Jordan during the academic year 2021–2022.

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Bruker. Apex4, Saint and Sadabs; Bruker AXS Inc.: Madison, Wisconsin, USA, 2021.Search in Google Scholar

2. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. Olex2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar

3. Sheldrick, G. M. Shelxt - integrated space-group and crystal-structure determination. Acta Crystallogr. 2015, A71, 3–8; https://doi.org/10.1107/s2053273314026370.Search in Google Scholar PubMed PubMed Central

4. Sheldrick, G. M. Crystal structure refinement with Shelxl. Acta Crystallogr. 2015, C71, 3–8, https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

5. Davies, W. L., Gruner, R. R., Haff, R. F., McGahen, J. W., Neumayer, E. M., Paulshock, M., Watts, J. C., Wood, T. R., Hermann, E. C., Hoffmann, C. E. Antiviral activity of 1-adamantanamine (amantadine). Science 1964, 144, 862–863; https://doi.org/10.1126/science.144.3620.862.Search in Google Scholar PubMed

6. Togo, Y., Hornick, R. B., Dawkins, A. T. Studies on induced influenza in Man I. Double-blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against A2/Rockville/1/65 strain. J. Am. Med. Assoc. 1968, 203, 1089–1094; https://doi.org/10.1001/jama.1968.03140130001001.Search in Google Scholar

7. Wanka, L., Iqba, l. K., Schreiner, P. R. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem. Rev. 2013, 113, 3516–3604; https://doi.org/10.1021/cr100264t.Search in Google Scholar PubMed PubMed Central

8. Shahin, A. I., Zaraei, S. O., AlKubaisi, B. O., Ullah, S., Anbar, H. S., El-Gamal, R., Menon, V., Abdel-Maksoud, M. S., Oh, C. H., El-Awady, R., Gelsleichter, N. E., Pelletier, J., Sévigny, J., Iqbal, J., Al-Tel, T. H., El-Gamal, M. I. Design and synthesis of new adamantyl derivatives as promising antiproliferative agents. Eur. J. Med. Chem. 2023, 246, 114958; https://doi.org/10.1016/j.ejmech.2022.114958.Search in Google Scholar PubMed

9. Al-Aboudi, A., Al-Qawasmeh, R. A., Shahwan, A., Mahmood, U., Khalid, A., Ul-Haq, Z. In-silico identification of the binding mode of synthesized adamantyl derivatives inside cholinesterase enzymes. Acta Pharmacol. Sin. 2015, 36, 879–886; https://doi.org/10.1038/aps.2014.173.Search in Google Scholar PubMed PubMed Central

10. Khanfar, M. A., Jaber, A. M., AlDamen, M. A., Al-Qawasmeh, R. A. Synthesis, characterization, crystal structure, and DFT study of a new square planar Cu(II) complex containing bulky adamantane ligand. Molecules 2018, 23, 701; https://doi.org/10.3390/molecules23030701.Search in Google Scholar PubMed PubMed Central

11. Jaber, A. M., Al-Mahadeen, M. M., Al-Qawasmeh, R. A., Taha, M. O. Design synthesis and antibacterial activity studies of new thiadiazoloquinolone compounds. Med. Chem. Res. 2023, 32, 2394–2404; https://doi.org/10.1007/s00044–023–03145–4.10.1007/s00044-023-03145-4Search in Google Scholar

12. Al-Qawasmeh, R. A., Hussein, N. A., Shehadi, I., Khanfar, M. A., Salameh, B. A. Design and synthesis of aminoacetylenic indole and carbazole hybrid compounds. ChemistrySelect 2020, 5, 6834–6839; https://doi.org/10.1002/slct.202001146.Search in Google Scholar

13. Lee, J., Jung, H., Kim, M., Lee, E., Im, D., Aman, W., Hah, J. Discovery of novel 4-aryl-thieno[1,4]diazepin-2-one derivatives targeting multiple protein kinases as anticancer agents. Bioorg. Med. Chem. 2018, 26, 1628–1637; https://doi.org/10.1016/j.bmc.2018.02.009.Search in Google Scholar PubMed

14. Hroch, L., Guest, P., Benek, O., Soukup, O., Janockova, J., Dolezal, R., Kuca, K., Aitken, L., Smith, T. K., Gunn-Moore, F., Zala, D., Ramsay, R. R., Musilek, K. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer s disease treatment. Bioorg. Med. Chem. 2017, 25, 1143–1152; https://doi.org/10.1016/j.bmc.2016.12.029.Search in Google Scholar PubMed

15. Li, Z., Liu, X., Zhao, T., Geng, P., Guo, W., Yu, B., Liu, H. Design, synthesis and preliminary biological evaluation of new [1,2,3]triazolo[4,5-d]pyrimidine/thiourea hybrids as antiproliferative agents. Eur. J. Med. Chem. 2017, 139, 741–749; https://doi.org/10.1016/j.ejmech.2017.08.042.Search in Google Scholar PubMed

16. Hersi, F., Omar, H. A., Al-Qawasmeh, R. A., Ahmad, Z., Jaber, A. M., Zaher, D. M., Al-Tel, T. H. Design and synthesis of new energy restriction mimetic agents: potent anti-tumor activities of hybrid motifs of aminothiazoles and coumarins. Sci. Rep. 2020, 19, 2893; https://doi.org/10.1038/s41598–020–59685-x.10.1038/s41598-020-59685-xSearch in Google Scholar PubMed PubMed Central

17. Al-Qawasmeh, R. A., Abadleh, M. M., Zahra, J. A., El-Abadelah, M. M., Albashiti, R., Zani, F., Incerti, M., Vicini, P. Design synthesis and antibacterial activity studies of new thiadiazoloquinolone compounds. J. Enzyme Inhib. Med. Chem. 2014, 29, 777–785; https://doi.org/10.3109/14756366.2013.855925.Search in Google Scholar PubMed

18. Bräse, S., Volz, N., Gläser, F., Nieger, M. Highly enantioselective access to cannabinoid-type tricyles by organocatalytic Diels–Alder reactions. Beilstein J. Org. Chem. 2012, 8, 1385–1392; https://doi.org/10.3762/bjoc.8.160.Search in Google Scholar PubMed PubMed Central

19. Abosadiya, H. M., Anouar, E. H., Hasbullah, S. A., Yamin B. M. Synthesis, X-ray, NMR, FT-IR, UV/vis, DFT and TD-DFT studies of N-(4-chlorobutanoyl)-N′-(2-3- and 4-methylphenyl)thiourea derivatives. Spectrochim. Acta, Part A 2015, 144, 115–124. https://doi.org/10.1016/j.saa.2015.01.092.Search in Google Scholar PubMed

Received: 2024-03-04
Accepted: 2024-03-27
Published Online: 2024-04-15
Published in Print: 2024-06-25

© 2024 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. The crystal structure of tris((Z)-2-hydroxy-N-((E)-pyridin-2-ylmethylene)benzohydrazonato-k2O,N)europium(III), C39H30N9O6Eu
  4. Crystal structure of (E)-3-(benzylideneamino)-2-phenylthiazolidin-4-one, C16H14N2OS
  5. The crystal structure of (E)-4-fluoro-N′-(1-(o-tolyl)ethylidene)benzohydrazide, C16H15FN2O
  6. Crystal structure of (6-chloropyridin-3-yl)methyl 2-(6-methoxynaphthalen-2-yl)propanoate, C20H18ClNO3
  7. Crystal structure of methyl 3-methoxy-4-(2-methoxy-2-oxoethoxy)benzoate, C12H14O6
  8. The crystal structure of bis[(4-methoxyphenyl)(picolinoyl)amido-κ2 N:N′]copper(II), C26H22CuN4O4
  9. The crystal structure of poly[di(μ2-aqua)-diaqua-bis(3-aminopyridine-4-carboxylate-κ2 O: O′)-tetra(μ2-3-aminopyridine-4-carboxylate-κ2 O: O′)-dineodymium(III), [Nd2(C6H5N2O2)6(H2O)4] n
  10. The crystal structure of t-butyl 7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoate, C28H34FNO4
  11. Crystal structure of catena-poly[(benzylamine-κ1 N)-(sorbato-κ1 O)-(μ2-sorbato-κ2 O,O′)-copper(II), C19H23CuNO4
  12. Crystal structure of (4-(2-chlorophenyl)-1H-pyrrol-3-yl)(ferrocenyl) methanone, C21H16ClFeNO
  13. The crystal structure of N-[4-(4-bromophenyl)-1,3-thiazol-2-yl]-3-(2-methylphenyl)-2-sulfanylprop-2-enamide hydrate, C19H17BrN2O2S2
  14. The crystal structure of N′-{5-[2-(2,6-dimethylphenoxy) acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl}-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide hydrate
  15. Crystal structure of 2-(naphthalen-1-yl)ethyl 2-(6-methoxynaphthalen-2-yl)propanoate, C26H24O3
  16. Crystal structure of naphthalen-1-ylmethyl 2-(6-methoxynaphthalen-2-yl)propanoate, C25H22O3
  17. Crystal structure of poly[diaqua- (μ4-5-(1H-1,2,4-triazol-1-yl)benzene-1,3-dicarboxylato-κ5N:O,O’:O’’:O’’’)calcium(II), C10H9CaN3O6
  18. Crystal structure of (E)-N′-(4-((E)-3-(dimethylamino)acryloyl)-3-hydroxyphenyl)-N, N-dimethylformimidamide, C14H19N3O2
  19. Crystal structure of (E)-3-(dimethylamino)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one, C13H17NO4
  20. Crystal structure of (2-chloropyridin-3-yl)methyl-2-(6-methoxynaphthalen-2-yl)propanoate, C20H18ClNO3
  21. The crystal structure of diethyl 4-(3,4-dimethylphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, C21H27NO4
  22. Crystal structure of (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-17-((4-(2-phenylpropyl)phenyl)ethynyl)-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one, C36H42O2
  23. Synthesis and crystal structure of 4-(4-cyclopropylnaphthalen-1-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione, C15H13N3S
  24. Crystal structure of catena-poly[aqua-(2,6-di-(2-pyridyl)-pyridine-κ3 N,N′, N″)(μ2-1,4-naphthalene dicarboxylato-κ2 O,O′)nickel(II)], C27H19NiN3O5
  25. Crystal structure of 3-(diphenylphosphoryl)-3-hydroxy-1-phenylpropan-1-one, C21H19O3P
  26. The crystal structure of R,S-{N-[(2-oxidonaphthalen-1-yl)methylidene]phenylglycinato}divinylsilicon, C23H19NO3Si
  27. The crystal structure of 1,2,4-tris(bromomethyl)benzene, C9H9Br3
  28. Crystal structure of chlorido-[4-(pyridin-2-yl)benzaldehyde-κ2 N,C]-(diethylamine-κ1 N)platinum(II), C16H18ClN2OPt
  29. Crystal structure of 3-(methoxycarbonyl)-1-(4-methoxyphenyl)-2,3,4,9- tetrahydro-1H-pyrido[3,4-b]indol-2-ium chloride hydrate, C40H48Cl2N4O9
  30. The crystal structure of 1-(2-chlorobenzyl)-3-(3-chlorophenyl)urea, C14H12Cl2N2O
  31. Hydrothermal synthesis and crystal structure of aqua-tris(4-acetamidobenzoato-κ2 O,O′)-(1,10-phenanthroline-κ2 N,N′)terbium(III) hydrate C39H36N5O11Tb
  32. The crystal structure of zwitterionic 3-aminoisonicotinic acid, C6H6N2O2
  33. The crystal structure of bis{[monoaqua-μ2-4-[(pyridine-4-carbonyl)-amino]-phthalato-κ3 N:O,O′-(2,2′-bipyridine κ2 N,N′)copper(II)]}decahydrate, C48H56N8O22Cu2
  34. Crystal structure of poly[μ10-4,4′-methylene-bis(oxy)benzoatodipotassium], C15H10K2O6
  35. The crystal structure of catena-poly[[tetraaqua[(μ2-1,4-di(4-methyl-1-imidazolyl)benzene] cobalt(II)]bis(formate)], C16H24CoN4O8
  36. The crystal structure of (E)-2-chloro-5-((2-(nitromethylene)imidazolidin-1-yl)methyl)pyridine, C10H11ClN4O2
  37. The crystal structure of (E)-1-(((2-amino-4,5-dimethylphenyl)iminio)methyl)naphthalen-2-olate, C19H18N2O
  38. Crystal structure of N-(acridin-9-yl)-2-(4-methylpiperidin-1-yl) acetamide monohydrate, C21H25N3O2
  39. The crystal structure of dichlorido-bis(3-methyl-3-imidazolium-1-ylpropionato-κ2 O,O′)-zinc(II), C14H20Cl2N4O4Zn
  40. The crystal structure of 2,8-diethyl-1,3,7,9-tetramethyl-4λ4,5λ4-spiro[dipyrrolo[1,2-c:2′,1′-f][1,3,2]diazaborinine-5,2′-naphtho[1,8-de][1,3,2]dioxaborinine], C25H29BN2O2
  41. The crystal structure of 5-tert-butyl-2-(5-tert-butyl-3-iodo-benzofuran-2-yl)-3-iodobenzofuran, C24H24I2O2
  42. Synthesis and crystal structure of methyl 2-{[4-(4-cyclopropyl-1-naphthyl)-4H-1,2,4-triazole-3-yl]thio} acetate, C18H17N3O2S
  43. The crystal structure of n-propylammonium bis(2,3-dimethylbutane-2,3-diolato)borate-boric acid (1/1), [C3H10N][C12H24BO4]·B(OH)3
  44. Crystal structure of methyl 1-(2-bromophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate, C19H17BrN2O2
  45. Crystal structure of (4-bromobenzyl)triphenylphosphonium bromide ethanol solvate, C52H48Br4OP2
  46. The crystal structure of unsymmetrical BOPHY C26H27BN4
  47. The crystal structure of Tb3B5O11(OH)2
  48. The crystal structure of (Z)-4-ethyl-2-((4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-3,5-dimethyl-2H-pyrrol-1-ium 2,2'-spirobi[naphtho[1,8-de][1,3,2]dioxaborinin]-2-uide, C37H37BN2O4
  49. Crystal structure of bis(methylammonium) hexadecaselenidopalladate(II), (CH3NH3)2PdSe16
  50. The crystal structure of (2-diphenylphosphanylphenyl) 2-[7-(dimethylamino)-2-oxochromen-4-yl]acetate, C31H26NO4P
  51. Crystal structure of (E)-6-(4-ethylpiperazin-1-yl)-2-(3-fluorobenzylidene)-3,4-dihydronaphthalen-1(2H)-one, C23H25FN2O
  52. The structure of RUB-56, (C6H16N)8 [Si32O64(OH)8]·32 H2O, a hydrous layer silicate (2D-zeolite) that contains microporous levyne-type silicate layers
  53. Crystal structure of 4-amino-3,5-dibromobenzonitrile, C7H4Br2N2
  54. Crystal structure of 2-(naphthalen-1-yl)ethyl 2-acetoxybenzoate, C21H18O4
  55. Single-crystal structure determination of Tm3B12O19(OH)7
  56. Crystal structure determination of NdB3.6O7
  57. The crystal structure of NdB6O8(OH)5·H3BO3
  58. Crystal structure of 2-(5-ethylpyridin-2-yl)ethyl 2-(6-methoxynaphthalen-2-yl)propanoate, C23H25NO3
  59. Crystal structure of N-(1-(3,4-dimethoxyphenyl)-2-methylpropyl)aniline, C18H23NO2
  60. Crystal structure of Ba6Cd12Mn4SiF48
  61. Synthesis and crystal structure of 5-fluoro-1-methyl-2-oxo-3-(2-oxochroman-4-yl)indolin-3-yl acetate, C20H16FNO5
  62. The crystal structure of 6-methacryloylbenzo[d][1,3]dioxol-5-yl 4-nitrobenzenesulfonate, C17H13NO8S
  63. Crystal structure of ethyl 2-(3-benzyl-4-oxo-3,4-dihydrophthalazin-1-yl)- 2,2-difluoroacetate, C19H16F2N2O3
  64. The crystal structure of tetrakis(μ 2-(1H-benzimidazole-2-methoxo-κ2 N,O:O:O)-(n-butanol-κO)-chlorido)-tetranickel(II), C48H68Cl4N8O8Ni4
  65. Synthesis and crystal structure of trans-tetraaqua-bis((1-((7-hydroxy-3-(4-methoxy-3-sulfonatophenyl)-4-oxo-4H-chromen-8-yl)methyl)piperidin-1-ium-4-carbonyl)oxy-κO)zinc(II)hexahydrate, C46H64N2O28S2Zn
  66. The crystal structure of 1-(4-carboxybutyl)-3-methyl-1H-imidazol-3-ium hexafluoridophosphate, C9H15F6N2O2P
  67. Crystal structure of 1-(4-chlorophenyl)-4-(2-furoyl)-3-phenyl-1H-pyrazol-5-ol, C20H13ClN2O3
  68. Crystal structure of dimethyl (R)-2-(3-(1-phenylethyl)thioureido)-[1,1′-biphenyl]-4,4′-dicarboxylate, C25H24N2O4S
  69. The crystal structure of 1-(3-carboxypropyl)-1H-imidazole-3-oxide, C7H10N2O3
  70. Synthesis and crystal structure of dimethyl 4,4′-(propane-1,3-diylbis(oxy))dibenzoate, C19H20O6
  71. Crystal structure of methyl-1-(p-tolyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate, C20H20N2O2
  72. The crystal structure of 1-(1-adamantan-1-yl)ethyl-3-(3-methoxyphenyl)thiourea, C20H28N2OS
  73. The crystal structure of N,N′-carbonylbis(2,6-difluorobenzamide), C15H8F4N2O3
https://doi.org/10.1515/ncrs-2024-0107
Creative Commons
BY 4.0

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. The crystal structure of tris((Z)-2-hydroxy-N-((E)-pyridin-2-ylmethylene)benzohydrazonato-k2O,N)europium(III), C39H30N9O6Eu
  4. Crystal structure of (E)-3-(benzylideneamino)-2-phenylthiazolidin-4-one, C16H14N2OS
  5. The crystal structure of (E)-4-fluoro-N′-(1-(o-tolyl)ethylidene)benzohydrazide, C16H15FN2O
  6. Crystal structure of (6-chloropyridin-3-yl)methyl 2-(6-methoxynaphthalen-2-yl)propanoate, C20H18ClNO3
  7. Crystal structure of methyl 3-methoxy-4-(2-methoxy-2-oxoethoxy)benzoate, C12H14O6
  8. The crystal structure of bis[(4-methoxyphenyl)(picolinoyl)amido-κ2 N:N′]copper(II), C26H22CuN4O4
  9. The crystal structure of poly[di(μ2-aqua)-diaqua-bis(3-aminopyridine-4-carboxylate-κ2 O: O′)-tetra(μ2-3-aminopyridine-4-carboxylate-κ2 O: O′)-dineodymium(III), [Nd2(C6H5N2O2)6(H2O)4] n
  10. The crystal structure of t-butyl 7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoate, C28H34FNO4
  11. Crystal structure of catena-poly[(benzylamine-κ1 N)-(sorbato-κ1 O)-(μ2-sorbato-κ2 O,O′)-copper(II), C19H23CuNO4
  12. Crystal structure of (4-(2-chlorophenyl)-1H-pyrrol-3-yl)(ferrocenyl) methanone, C21H16ClFeNO
  13. The crystal structure of N-[4-(4-bromophenyl)-1,3-thiazol-2-yl]-3-(2-methylphenyl)-2-sulfanylprop-2-enamide hydrate, C19H17BrN2O2S2
  14. The crystal structure of N′-{5-[2-(2,6-dimethylphenoxy) acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl}-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide hydrate
  15. Crystal structure of 2-(naphthalen-1-yl)ethyl 2-(6-methoxynaphthalen-2-yl)propanoate, C26H24O3
  16. Crystal structure of naphthalen-1-ylmethyl 2-(6-methoxynaphthalen-2-yl)propanoate, C25H22O3
  17. Crystal structure of poly[diaqua- (μ4-5-(1H-1,2,4-triazol-1-yl)benzene-1,3-dicarboxylato-κ5N:O,O’:O’’:O’’’)calcium(II), C10H9CaN3O6
  18. Crystal structure of (E)-N′-(4-((E)-3-(dimethylamino)acryloyl)-3-hydroxyphenyl)-N, N-dimethylformimidamide, C14H19N3O2
  19. Crystal structure of (E)-3-(dimethylamino)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one, C13H17NO4
  20. Crystal structure of (2-chloropyridin-3-yl)methyl-2-(6-methoxynaphthalen-2-yl)propanoate, C20H18ClNO3
  21. The crystal structure of diethyl 4-(3,4-dimethylphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, C21H27NO4
  22. Crystal structure of (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-17-((4-(2-phenylpropyl)phenyl)ethynyl)-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one, C36H42O2
  23. Synthesis and crystal structure of 4-(4-cyclopropylnaphthalen-1-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione, C15H13N3S
  24. Crystal structure of catena-poly[aqua-(2,6-di-(2-pyridyl)-pyridine-κ3 N,N′, N″)(μ2-1,4-naphthalene dicarboxylato-κ2 O,O′)nickel(II)], C27H19NiN3O5
  25. Crystal structure of 3-(diphenylphosphoryl)-3-hydroxy-1-phenylpropan-1-one, C21H19O3P
  26. The crystal structure of R,S-{N-[(2-oxidonaphthalen-1-yl)methylidene]phenylglycinato}divinylsilicon, C23H19NO3Si
  27. The crystal structure of 1,2,4-tris(bromomethyl)benzene, C9H9Br3
  28. Crystal structure of chlorido-[4-(pyridin-2-yl)benzaldehyde-κ2 N,C]-(diethylamine-κ1 N)platinum(II), C16H18ClN2OPt
  29. Crystal structure of 3-(methoxycarbonyl)-1-(4-methoxyphenyl)-2,3,4,9- tetrahydro-1H-pyrido[3,4-b]indol-2-ium chloride hydrate, C40H48Cl2N4O9
  30. The crystal structure of 1-(2-chlorobenzyl)-3-(3-chlorophenyl)urea, C14H12Cl2N2O
  31. Hydrothermal synthesis and crystal structure of aqua-tris(4-acetamidobenzoato-κ2 O,O′)-(1,10-phenanthroline-κ2 N,N′)terbium(III) hydrate C39H36N5O11Tb
  32. The crystal structure of zwitterionic 3-aminoisonicotinic acid, C6H6N2O2
  33. The crystal structure of bis{[monoaqua-μ2-4-[(pyridine-4-carbonyl)-amino]-phthalato-κ3 N:O,O′-(2,2′-bipyridine κ2 N,N′)copper(II)]}decahydrate, C48H56N8O22Cu2
  34. Crystal structure of poly[μ10-4,4′-methylene-bis(oxy)benzoatodipotassium], C15H10K2O6
  35. The crystal structure of catena-poly[[tetraaqua[(μ2-1,4-di(4-methyl-1-imidazolyl)benzene] cobalt(II)]bis(formate)], C16H24CoN4O8
  36. The crystal structure of (E)-2-chloro-5-((2-(nitromethylene)imidazolidin-1-yl)methyl)pyridine, C10H11ClN4O2
  37. The crystal structure of (E)-1-(((2-amino-4,5-dimethylphenyl)iminio)methyl)naphthalen-2-olate, C19H18N2O
  38. Crystal structure of N-(acridin-9-yl)-2-(4-methylpiperidin-1-yl) acetamide monohydrate, C21H25N3O2
  39. The crystal structure of dichlorido-bis(3-methyl-3-imidazolium-1-ylpropionato-κ2 O,O′)-zinc(II), C14H20Cl2N4O4Zn
  40. The crystal structure of 2,8-diethyl-1,3,7,9-tetramethyl-4λ4,5λ4-spiro[dipyrrolo[1,2-c:2′,1′-f][1,3,2]diazaborinine-5,2′-naphtho[1,8-de][1,3,2]dioxaborinine], C25H29BN2O2
  41. The crystal structure of 5-tert-butyl-2-(5-tert-butyl-3-iodo-benzofuran-2-yl)-3-iodobenzofuran, C24H24I2O2
  42. Synthesis and crystal structure of methyl 2-{[4-(4-cyclopropyl-1-naphthyl)-4H-1,2,4-triazole-3-yl]thio} acetate, C18H17N3O2S
  43. The crystal structure of n-propylammonium bis(2,3-dimethylbutane-2,3-diolato)borate-boric acid (1/1), [C3H10N][C12H24BO4]·B(OH)3
  44. Crystal structure of methyl 1-(2-bromophenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate, C19H17BrN2O2
  45. Crystal structure of (4-bromobenzyl)triphenylphosphonium bromide ethanol solvate, C52H48Br4OP2
  46. The crystal structure of unsymmetrical BOPHY C26H27BN4
  47. The crystal structure of Tb3B5O11(OH)2
  48. The crystal structure of (Z)-4-ethyl-2-((4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-3,5-dimethyl-2H-pyrrol-1-ium 2,2'-spirobi[naphtho[1,8-de][1,3,2]dioxaborinin]-2-uide, C37H37BN2O4
  49. Crystal structure of bis(methylammonium) hexadecaselenidopalladate(II), (CH3NH3)2PdSe16
  50. The crystal structure of (2-diphenylphosphanylphenyl) 2-[7-(dimethylamino)-2-oxochromen-4-yl]acetate, C31H26NO4P
  51. Crystal structure of (E)-6-(4-ethylpiperazin-1-yl)-2-(3-fluorobenzylidene)-3,4-dihydronaphthalen-1(2H)-one, C23H25FN2O
  52. The structure of RUB-56, (C6H16N)8 [Si32O64(OH)8]·32 H2O, a hydrous layer silicate (2D-zeolite) that contains microporous levyne-type silicate layers
  53. Crystal structure of 4-amino-3,5-dibromobenzonitrile, C7H4Br2N2
  54. Crystal structure of 2-(naphthalen-1-yl)ethyl 2-acetoxybenzoate, C21H18O4
  55. Single-crystal structure determination of Tm3B12O19(OH)7
  56. Crystal structure determination of NdB3.6O7
  57. The crystal structure of NdB6O8(OH)5·H3BO3
  58. Crystal structure of 2-(5-ethylpyridin-2-yl)ethyl 2-(6-methoxynaphthalen-2-yl)propanoate, C23H25NO3
  59. Crystal structure of N-(1-(3,4-dimethoxyphenyl)-2-methylpropyl)aniline, C18H23NO2
  60. Crystal structure of Ba6Cd12Mn4SiF48
  61. Synthesis and crystal structure of 5-fluoro-1-methyl-2-oxo-3-(2-oxochroman-4-yl)indolin-3-yl acetate, C20H16FNO5
  62. The crystal structure of 6-methacryloylbenzo[d][1,3]dioxol-5-yl 4-nitrobenzenesulfonate, C17H13NO8S
  63. Crystal structure of ethyl 2-(3-benzyl-4-oxo-3,4-dihydrophthalazin-1-yl)- 2,2-difluoroacetate, C19H16F2N2O3
  64. The crystal structure of tetrakis(μ 2-(1H-benzimidazole-2-methoxo-κ2 N,O:O:O)-(n-butanol-κO)-chlorido)-tetranickel(II), C48H68Cl4N8O8Ni4
  65. Synthesis and crystal structure of trans-tetraaqua-bis((1-((7-hydroxy-3-(4-methoxy-3-sulfonatophenyl)-4-oxo-4H-chromen-8-yl)methyl)piperidin-1-ium-4-carbonyl)oxy-κO)zinc(II)hexahydrate, C46H64N2O28S2Zn
  66. The crystal structure of 1-(4-carboxybutyl)-3-methyl-1H-imidazol-3-ium hexafluoridophosphate, C9H15F6N2O2P
  67. Crystal structure of 1-(4-chlorophenyl)-4-(2-furoyl)-3-phenyl-1H-pyrazol-5-ol, C20H13ClN2O3
  68. Crystal structure of dimethyl (R)-2-(3-(1-phenylethyl)thioureido)-[1,1′-biphenyl]-4,4′-dicarboxylate, C25H24N2O4S
  69. The crystal structure of 1-(3-carboxypropyl)-1H-imidazole-3-oxide, C7H10N2O3
  70. Synthesis and crystal structure of dimethyl 4,4′-(propane-1,3-diylbis(oxy))dibenzoate, C19H20O6
  71. Crystal structure of methyl-1-(p-tolyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate, C20H20N2O2
  72. The crystal structure of 1-(1-adamantan-1-yl)ethyl-3-(3-methoxyphenyl)thiourea, C20H28N2OS
  73. The crystal structure of N,N′-carbonylbis(2,6-difluorobenzamide), C15H8F4N2O3
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 26.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2024-0107/html
Scroll to top button